Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Receivables - Net: 2009-2025

Historic Receivables - Net for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to $15.2 million.

  • Lifecore Biomedical's Receivables - Net fell 6.90% to $15.2 million in Q2 2025 from the same period last year, while for May 2025 it was $15.2 million, marking a year-over-year decrease of 6.90%. This contributed to the annual value of $15.2 million for FY2025, which is 6.90% down from last year.
  • Latest data reveals that Lifecore Biomedical reported Receivables - Net of $15.2 million as of Q2 2025, which was down 6.10% from $16.1 million recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical's Receivables - Net registered a high of $39.7 million during Q1 2022, and its lowest value of $15.2 million during Q2 2025.
  • For the 3-year period, Lifecore Biomedical's Receivables - Net averaged around $21.9 million, with its median value being $19.4 million (2023).
  • Per our database at Business Quant, Lifecore Biomedical's Receivables - Net slumped by 58.63% in 2021 and then spiked by 63.04% in 2024.
  • Quarterly analysis of 5 years shows Lifecore Biomedical's Receivables - Net stood at $27.5 million in 2021, then decreased by 0.13% to $27.5 million in 2022, then declined by 29.23% to $19.4 million in 2023, then skyrocketed by 58.84% to $30.9 million in 2024, then dropped by 6.90% to $15.2 million in 2025.
  • Its last three reported values are $15.2 million in Q2 2025, $16.1 million for Q1 2025, and $30.9 million during Q4 2024.